Effect of intensive atorvastatin therapy on periprocedural PDCD4 expression in CD4+ T lymphocytes of patients with unstable angina undergoing percutaneous coronary intervention

Cardiology (Switzerland)

Volumn 127, Issue 3, 2014, Pages 169-175

  Su, Qiang ^a   Li, Lang ^a   Liu, Yang ^a   Zhou, You ^a   Wang, Jiangyou ^a   Sun, Yuhan ^a  

^a FIRST AFFILIATED HOSPITAL OF GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

Atorvastatin; Programmed cell death 4; Unstable angina

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; CLOPIDOGREL; CREATINE KINASE; HEPARIN; INTERLEUKIN 10; LYMPHOCYTE ANTIGEN; PROGRAMMED CELL DEATH 4; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; CELL PROTEIN; CREATINE KINASE MB; MESSENGER RNA;

ADULT; ANTIGEN EXPRESSION; ARTICLE; CD4+ T LYMPHOCYTE; CELL SELECTION; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HEART MUSCLE INJURY; HUMAN; INCIDENCE; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PERIPROCEDURAL MYOCARDIAL INJURY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; REAL TIME POLYMERASE CHAIN REACTION; UNSTABLE ANGINA PECTORIS; WESTERN BLOTTING; AGED; ANGIOCARDIOGRAPHY; CARDIAC PATIENT; CARDIOVASCULAR RISK; CORONARY ARTERY OBSTRUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; QUANTITATIVE ANALYSIS;

AGED; ANGINA, UNSTABLE; APOPTOSIS REGULATORY PROTEINS; C-REACTIVE PROTEIN; CD4-POSITIVE T-LYMPHOCYTES; CREATINE KINASE, MB FORM; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INTERLEUKIN-10; MALE; PERCUTANEOUS CORONARY INTERVENTION; PYRROLES; RNA, MESSENGER; RNA-BINDING PROTEINS; TROPONIN I; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84892430722     PISSN: 00086312     EISSN: 14219751     Source Type: Journal    
DOI: 10.1159/000356434     Document Type: Article

References (21)

1. Nusca A, Melfi R, Patti G, Sciascio GD: Statin loading before percutaneous coronary intervention: Proposed mechanisms and applications. Future Cardiol 2010; 6: 579-589
2. Patti G, Pasceri V, Colonna G, et al: Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: Results of the ARMYDA-ACS randomized trial. J Am Coll Cardiol 2007; 49: 1272-1278
3. Pasceri V, Patti G, Nusca A, Pristipino C, Richichi G, Di Sciascio G: Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: Results from the ARMYDA (Atorvastatin for Reduction of Myocardial Damage during Angioplasty) study. Circulation 2004; 110: 674-678
4. Di Sciascio G, Patti G, Pasceri V, Gaspardone A, Colonna G, Montinaro A: Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: Results of the ARMYDA-RECAPTURE( Atorvastatin for Reduction of Myocardial Damage During Angioplasty) Randomized Trial. J Am Coll Cardiol 2009; 54: 558-565
5. Patti G, Chello M, Pasceri V, et al: Protection from procedural myocardial injury by atorvastatin is associated with lower levels of adhesion molecules after percutaneous coronary intervention: Results from the ARMYDACAMs( Atorvastatin for Reduction of Myocardial Damage during Angioplasty-Cell Adhesion Molecules) substudy. J Am Coll Cardiol 2006; 48: 1560-1566
6. Tanaka T, Soejima H, Hirai N, et al: Comparison of frequency of interferon-?-positive CD4+ T cells before and after percutaneous coronary intervention and the effect of statin therapy in patients with stable angina pectoris. Am J Cardiol 2004; 93: 1547-1549
7. George J, Shmuel SB, Roth A, et al: L -arginine attenuates lymphocyte activation and antioxidized LDL antibody levels in patients undergoing angioplasty. Atherosclerosis 2004; 174: 323-327
8. Dumitriu IE, Baruah P, Finlayson CJ, et al: High levels of costimulatory receptors OX40 and 4-1BB characterize CD4 + CD28 null T cells in patients with acute coronary syndrome. Circ Res 2012; 110: 857-869
9. Hilliard A, Hilliard B, Zheng SJ, et al: Translational regulation of autoimmune inflammation and lymphoma genesis by programmed cell death 4. J Immunol 2006; 177: 8095-8102
10. Arroyo-Villa I, Bautista-Caro MB, Balsa A, et al: Frequency of Th17 CD4+ T cells in early rheumatoid arthritis: A marker of anti-CCP seropositivity. PLoS One 2012; 7:e42189
11. Methe H, Brunner S, Wiegand D, Nabauer M, Koglin J, Edelman ER: Enhanced T-helper-1 lymphocyte activation patterns in acute coronary syndromes. J Am Coll Cardiol 2005; 45: 1939-1945
12. Sheedy FJ, Palsson-McDermott E, Hennessy EJ, et al: Negative regulation of TLR4 via targeting of the proinflammatory tumor suppressor PDCD4 by the microRNA miR-21. Nat Immunol 2010; 11: 141-147
13. Yasuda M, Schmid T, Rubsamen D, Colburn NH, Irie K, Murakami A: Downregulation of programmed cell death 4 by inflammatory conditions contributes to the generation of the tumor promoting microenvironment. Mol Carcinog 2010; 49: 837-848
14. Novack V, Pencina M, Cohen DJ, et al: Troponin criteria for myocardial infarction after percutaneous coronary intervention. Arch Intern Med 2012; 172: 502-508
15. Bu DX, Griffin G, Lichtman AH: Mechanisms for the anti-inflammatory effects of statins. Curr Opin Lipidol 2011; 22: 165-170
16. Weitz-Schmidt G, Welzenbach K, Brinkmann V, et al: Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 2001; 7: 687-692
17. Cheng X, Ding Y, Xia C, et al: Atorvastatin modulates Th1/Th2 response in patients with chronic heart failure. J Card Fail 2009; 15: 158-162
18. Tawfik MK, Ghattas MH, Abo-Elmatty DM, Abdel-Aziz NA: Atorvastatin restores the balance between pro-inflammatory and anti-inflammatory mediators in rats with acute myocardial infarction. Eur Rev Med Pharmacol Sci 2010; 14: 499-506
19. Cmarik JL, Min H, Hegamyer G, et al: Differentially expressed protein Pdcd4 inhibits tumor promoter-induced neoplastic transformation. Proc Natl Acad Sci USA 1999; 96: 14037-14042
20. Afonja O, Juste D, Das S, et al: Induction of PDCD4 tumor suppressor gene expression by RAR agonists, antiestrogen and HER-2/neu antagonist in breast cancer cells: Evidence for a role in apoptosis. Oncogene 2004; 23: 8135-8145
21. Woodard J, Sassano A, Hay N, et al: Statindependent suppression of the Akt/mammalian target of rapamycin signaling cascade and programmed cell death 4 up-regulation in renal cell carcinoma. Clin Cancer Res 2008; 14: 4640-4649